Translational Oncology (Apr 2016)

Dynamic Quantitative T1 Mapping in Orthotopic Brain Tumor Xenografts

  • Kelsey Herrmann,
  • Bernadette O. Erokwu,
  • Mette L. Johansen,
  • James P. Basilion,
  • Vikas Gulani,
  • Mark A. Griswold,
  • Chris A. Flask,
  • Susann M. Brady-Kalnay

DOI
https://doi.org/10.1016/j.tranon.2016.02.004
Journal volume & issue
Vol. 9, no. 2
pp. 147 – 154

Abstract

Read online

Human brain tumors such as glioblastomas are typically detected using conventional, nonquantitative magnetic resonance imaging (MRI) techniques, such as T2-weighted and contrast enhanced T1-weighted MRI. In this manuscript, we tested whether dynamic quantitative T1 mapping by MRI can localize orthotopic glioma tumors in an objective manner. Quantitative T1 mapping was performed by MRI over multiple time points using the conventional contrast agent Optimark. We compared signal differences to determine the gadolinium concentration in tissues over time. The T1 parametric maps made it easy to identify the regions of contrast enhancement and thus tumor location. Doubling the typical human dose of contrast agent resulted in a clearer demarcation of these tumors. Therefore, T1 mapping of brain tumors is gadolinium dose dependent and improves detection of tumors by MRI. The use of T1 maps provides a quantitative means to evaluate tumor detection by gadolinium-based contrast agents over time. This dynamic quantitative T1 mapping technique will also enable future quantitative evaluation of various targeted MRI contrast agents.